Celgene Corp. (CELG) Releases FY13 Earnings Guidance
Celgene Corp. (NASDAQ:CELG) updated its FY13 earnings guidance on Thursday. The company provided earnings per share guidance of $5.90-5.95 for the period, compared to the Thomson Reuters consensus earnings per share estimate of $5.94, American Banking and Market News reports.
A number of research firms have recently commented on CELG. Analysts at RBC Capital raised their price target on shares of Celgene Corp. from $150.00 to $170.00 in a research note to investors on Wednesday, October 9th. They now have an outperform rating on the stock. On a related note, analysts at Bank of America Corp. raised their price target on shares of Celgene Corp. from $164.00 to $179.00 in a research note to investors on Tuesday, October 8th. They now have a buy rating on the stock. Finally, analysts at TheStreet reiterated a buy rating on shares of Celgene Corp. in a research note to investors on Monday, October 7th. Five analysts have rated the stock with a hold rating and twenty-three have given a buy rating to the company. The company currently has an average rating of Buy and an average price target of $145.15.
Celgene Corp. (NASDAQ:CELG) opened at 160.00 on Thursday. Celgene Corp. has a 52 week low of $70.42 and a 52 week high of $151.00. The stock has a 50-day moving average of $142.3 and a 200-day moving average of $125.4. The company has a market cap of $65.804 billion and a P/E ratio of 44.74.
Celgene Corp. (NASDAQ:CELG) last released its earnings data on Thursday, October 24th. The company reported $1.56 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.54 by $0.02. The company had revenue of $1.67 billion for the quarter, compared to the consensus estimate of $1.64 billion. During the same quarter in the previous year, the company posted $1.29 earnings per share. The company’s revenue for the quarter was up 18.0% on a year-over-year basis. On average, analysts predict that Celgene Corp. will post $5.98 earnings per share for the current fiscal year.
Celgene Corporation is a global biopharmaceutical company engaged in the discovery, development and commercialization of therapies designed to treat cancer and immune-inflammatory related diseases.
Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.